hexamethonium has been researched along with Apoplexy in 1 studies
Hexamethonium: A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gulliford, M | 1 |
| Charlton, J | 1 |
| Bhattarai, N | 1 |
| Rudisill, C | 1 |
1 other study available for hexamethonium and Apoplexy
| Article | Year |
|---|---|
Social and material deprivation and the cost-effectiveness of an intervention to promote physical activity: cohort study and Markov model.
Topics: Adult; Cardiovascular Diseases; Chronic Disease; Cohort Studies; Cost-Benefit Analysis; Cultural Dep | 2014 |